Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Abaloparatide in Patients with Osteoporosis
jRCT2080223520Phase 3Completed
- Sponsor
- Teijin Pharma
- Start
- May 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing Abaloparatide 80 mcg with Placebo (2 arms). Primary endpoint: Percent change in lumbar (L1–L4) bone mineral density at last visit. Started May 2017; status: completed.
02
Drugs
abaloparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT2080223520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223520.